Found 11 matching trials
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A PHASE1 Sobi.BIVV001-003 is an open-label, 2-period, fixed sequence study for intra...
Show More Location
Sobi Investigational Site
Learn More & Join Trial
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan N/A This is a national, multicenter, retrospective/prospective, observational s...
Show More Location
Investigational Site Number : 1580008
Learn More & Join Trial
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A PHASE3 Primary Objective:
\- To evaluate the long-term safety of BIVV001 in previ...
Show More Status
Active Not Recruiting
Location
Orthopaedic Institute for Children Site Number : 8400003
Learn More & Join Trial
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A PHASE1 Primary objective
âą To assess the half-life of BIVV001, Standard Half-Life...
Show More Location
Investigational Site Number :1000001
Learn More & Join Trial
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A N/A This is a prospective, observational, multi-center longitudinal cohort stud...
Show More Status
Active Not Recruiting
Location
Banner MD Anderson Cancer Center- Site Number : 8400008
Learn More & Join Trial
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A PHASE3 Primary Objective:
\- To evaluate the safety of BIVV001 in previously trea...
Show More Location
Children's Hospital Los Angeles-Site Number:8400006
Learn More & Join Trial
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD) PHASE1 Primary Objective:
-To characterize the pharmacokinetics (PK) of BIVV001 a...
Show More Location
University of Iowa_Investigational Site Number :8400002
Learn More & Join Trial
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A PHASE3 Primary Objective:
\- To evaluate the efficacy of BIVV001 as a prophylaxis...
Show More Location
Investigational Site Number 920
Learn More & Join Trial
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients â„12 Years Treated Once Weekly With Efanesoctocog Alfa PHASE3 FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe ...
Show More Location
Investigational Site
Learn More & Join Trial
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy PHASE4 The objective of the study is to assess the improvement of synovial hypertr...
Show More Location
Orthopedic Institute for Children- Site Number : 8400009
Learn More & Join Trial